Skip to content
229,518 profiles ranked

Napoleone Ferrara

Italian molecular biologist · United States · On the map · Scientists · Born 1956 · age 70

Napoleone Ferrara is an Italian-American molecular biologist who joined University of California, San Diego Moores Cancer Center in 2013 after a career in Northern California at the biotechnology giant Genentech, where he pioneered the development of new treatments for angiogenic diseases such as cancer, age-related macular degeneration (AMD), and diabetic retinopathy.

Napoleone Ferrara is read about 17 times a day, in 12 languages.

A typical day, 30 days to 9 October 2026

The middle day of the days counted, so one week of news cannot move it. The line under it is the last 120 days, one point a day.

Something wrong?
Compare Claim

A life in dates

2018Clarivate Citation LaureatesAward2014Canada Gairdner International AwardAwardChampalimaud Vision AwardAward2013Breakthrough Prize in Life SciencesAward2011Dr. Paul Janssen Award for Biomedical ResearchAward2010Lasker-DeBakey Clinical Medical Research AwardAward2005Scientific Grand Prize of the Lefoulon-Delalande FondationAward1956Born26 July 1956

Awards

Clarivate Citation Laureates2018
Canada Gairdner International Award2014
Champalimaud Vision Award2014
Breakthrough Prize in Life Sciences2013
Dr. Paul Janssen Award for Biomedical Research2011
Lasker-DeBakey Clinical Medical Research Award2010
Scientific Grand Prize of the Lefoulon-Delalande Fondation2005

About this person

At Genentech, he discovered VEGF - and made the first anti-VEGF antibody - which suppresses growth of a variety of tumors. These findings helped lead to development and FDA approval of the first clinically effective angiogenesis inhibitor, bevacizumab (Avastin), which prevents the growth of new blood vessels into a solid tumor. Bevacizumab, first approved for treatment of metastatic colorectal cancer in 2004, has become part of standard treatment for a variety of cancers. Ferrara's work led also to the development of ranibizumab (Lucentis), a drug that is highly effective at preventing vision loss in patients with intraocular neovascular disorders such as neovascular AMD and retinal vein occlusion. Ranibizumab and other anti-VEGF agents represent the first effective therapy for such blinding disorders and rank among the most widely used drugs in older adults.

Country
United States
Category
Scientists
Type
Scientist
Status
Living
Dates
Born 1956 · age 70